SAN ANTONIO—In the era of increasingly high prices for some orphan drugs and for gene and cell therapies, health plans are turning to reinsurance and stop-loss programs to help reduce their risk, according to a presentation at AMCP 2023.
Reinsurance and stop-loss programs provide balance-sheet protection to payors by reimbursing catastrophic costs, said Rick Lassow, FSA, MAAA, the vice president of actuarial and underwriting for Summit Re, a managing general underwriter and